Traditional approaches to exploit innate immunity for cancer immunotherapy include the activation of endogenous effectors (mainly NK cells) with systemic administration of cytokines (IL-2, etc.)and the adoptive infusion of ex vivo expanded NK or lymphokine-activated killer (LAK) cells. This evidence concerns the gene IL2 and cancer.